November 14, 2022 11:11 AM EST
R&D
FDA+

Af­ter CRL, drug de­vel­op­er duo re­sub­mits its ex­per­i­men­tal drug to the FDA, look­ing to com­pete with Fab­razyme

Max Gelman

Senior Editor

About a year and a half af­ter get­ting turned away from the FDA, a pair of drug de­vel­op­ers is head­ing back for a sec­ond chance …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times